A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PACIFIC
- Sponsors AstraZeneca
- 31 Jul 2017 According to a MedImmune media release, basis on the interim results of this study the US FDA has granted Breakthrough Therapy Designation for IMFINZI (durvalumab), for the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.
- 26 May 2017 According to an AstraZeneca media release, data from this study will be presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2017.
- 12 May 2017 Independent Data Monitoring Committee (IDMC) conducted a planned interim analysis and concluded that the trial has already met a primary endpoint, according to a AstraZeneca media release.